Arvinas has initiated a deal with Novartis that encompasses a worldwide licensing pact to advance and market their PROTAC® technology-based AR degrader ARV-766, aimed at prostate cancer therapies.

Alpine Immune Sciences Reports New Clinical Data for Povetacicept in IgA Nephropathy.

Macomics Discloses Pioneering Anti-Pan-LILRB Antibody Initiative, Showcasing Encouraging Preclinical Results at 2024 AACR Event.

Tallac Therapeutics Unveils Novel Preclinical Findings for TAC-001 Paired with Oncology Vaccines at AACR's 2024 Yearly Convention.

At the AACR 2024, Crescendo Biologics showcased early-stage findings for its primary investigational drug, CB307, while also revealing CB699, their inaugural dual-functioning immune cell attractor.

Monopar Therapeutics Launches Phase 1 Trial for Novel MNPR-101-Zr Diagnostic Molecule.

Nurix Therapeutics Announces Initial Clinical Signs of Brain Activity for NX-5948, an Orally Administered Compound That Crosses Blood-Brain Barrier and Targets BTK for Treating B Cell Cancers.

Foghorn Therapeutics Unveils Novel Early-Stage Research Findings for Unique BRM Targeted Inhibitor FHD-909 and Distinct CBP & EP300 Degrader Initiatives in Cancer Treatment.

Fusion Pharmaceuticals Reveals Preliminary Results of Phase 2 TATCIST Study on FPI-2265 During AACR 2024 Convention.

Innate Pharma Showcases Pre-IND Candidate IPH45's Preclinical Results at AACR 2024 - A New Antibody-Drug Conjugate Targeting Nectin-4.

Synthekine Unveils Encouraging Early Outcomes from Early-stage Clinical Study of Altered IL-2 Agent, STK-012, Aimed at Advanced Solid Cancer Therapy.

Obsidian Therapeutics Reveals Encouraging Safety and Effectiveness Results After 25 Weeks of Monitoring in Initial Human Trials for OBX-115.